<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928484</url>
  </required_header>
  <id_info>
    <org_study_id>CIEN-HUCA-IPLA</org_study_id>
    <nct_id>NCT02928484</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of a Probiotic Supplement Upon Gastrointestinal Function</brief_title>
  <official_title>Evaluación Del Efecto Del Suplemento Nutricional probiótico &quot;Biopolis&quot; Sobre la función Gastrointestinal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biopolis S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Central de Asturias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biopolis S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate whether a probiotic supplement improves
      gastrointestinal (GI) function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty volunteers with functional GI disorders (Functional dyspepsia according to Rome-III
      criteria) will be recruited for a randomised, double-blind, placebo-controlled, two-arm
      parallel study in which the effect upon the gastrointestinal function of a probiotic mix
      containing bifidobacteria and lactobacilli (manufactured by Biopolis SL) will be compared
      with placebo (maltodextrin). The study design includes a 4 week run-in period, in which the
      volunteers will not consume any probiotics/prebiotics, followed by a 4 weeks intervention
      period (a daily capsule of placebo or probiotic) and an 8 weeks washout period. At the
      beginning/end of each period questionnaires in gastrointestinal function, dyspepsia related
      symptoms and diet will be carried out. A serum sample will be taken for cytokine levels
      determination. A faecal sample will be taken for 16S microbial population profiling and for
      determining the faecal levels of Bifidobacterium, Bacteriodes, Faecalibacterium, Akkermansia,
      Lactobacillus and Blautia by qPCR and the concentration of the main bacterial metabolites;
      acetate, propionate and butyrate by gas-chromatography.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional dyspepsia symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Physician determined symptoms according to Rome III criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative proportions of the main microbial groups of the intestinal microbiota</measure>
    <time_frame>3 months</time_frame>
    <description>Global profile of intestinal microbiota composition established by 16S rRNA profiling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspepsia associated quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Questionaires for symptoms and QoL associated to dyspepsia and for anxiety/depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IFN-gamma levels</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the serum concentration (pg/mL) of IFN-gamma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TNF-alpha levels</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the serum concentration (pg/mL) of TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IL-12 levels</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the serum concentration (pg/mL) of IL-12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IL-4 levels</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the serum concentration (pg/mL) of IL-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IL-10 levels</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the serum concentration (pg/mL) of IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TGF-beta levels</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the serum concentration (pg/mL) of TGF-beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal levels of Bifidobacterium</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the levels (log cells/gr) of Bifidobacterium in fecal samples by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal levels of Lactobacillus</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the levels (log cells/gr) of Lactobacillus in fecal samples by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal levels of Bacteroides</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the levels (log cells/gr) of Bacteroides in fecal samples by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal levels of Blautia</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the levels (log cells/gr) of Blautia in fecal samples by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal levels of Akkermansia</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the levels (log cells/gr) of Akkermansia in fecal samples by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal levels of Faecalibacterium</measure>
    <time_frame>3 months</time_frame>
    <description>Determination of the levels (log cells/gr) of Faecalibacterium in fecal samples by qPCR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Signs and Symptoms, Digestive</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic mix CBP-004019/C</intervention_name>
    <description>One capsule per day of the probiotic mix CBP-004019/C during one month.</description>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule per day of the placebo (maltodextrin) during one month.</description>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional dyspepsia (type postprandial distress or postprandial distress plus
             epigastric pain) diagnosed according to Rome III criteria

        Exclusion Criteria:

          -  Celiac disease or other organic GI disease

          -  Orthorexia nervosa or other eating disorders

          -  Special dietary patterns (vegans, vegetarians, macrobiotic, exclusion diets, etc.)

          -  Extreme BMI (&lt;18,8 or &gt; 39,9)

          -  Metabolic disorders

          -  Positive Helicobacter pylori test

          -  Congenital IgA deficiency

          -  Lactose malabsorption/intolerance

          -  SIBO

          -  Diabetes

          -  Scleroderma, CREST, lupus or other connective tissue diseases

          -  Previous GI surgery or neoplastic disease

          -  Treatment with non steroidal anti-inflammatory drugs and/or acetyl salicylic acid.

          -  Pregnancy

          -  Menopause
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adolfo Suárez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Central de Asturias, Servicio de Gastroenterología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Gueimonde, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consejo Superior de Investigaciones Científicas, IPLA-CSIC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Empar Chenol, PhD</last_name>
    <phone>+34963160299</phone>
    <email>empar.chenoll@biopolis.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvador Genoves, PhD</last_name>
    <phone>+34963160299</phone>
    <email>salvador.genoves@biopolis.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Suárez, MD, PhD</last_name>
      <phone>+34985108000</phone>
      <email>adolfo.suarez@hcabuenes.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional dyspepsia</keyword>
  <keyword>Abdominal pain</keyword>
  <keyword>Flatulence</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Bifidobacterium</keyword>
  <keyword>Lactobacillus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Signs and Symptoms, Digestive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

